Novo Nordisk A/S, of Bagsværd, Denmark, said a securities lawsuit has been filed in Denmark against the company by a number of shareholders who are claiming DKK11.785 billion (US$1.75 billion) based on their trading and holding of shares in Novo Nordisk during the period of Feb. 3, 2015, to Feb. 2, 2017. It alleges that the company made misleading statements and did not make appropriate disclosures regarding its sales of insulin products in the U.S.